• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bellerophon Therapeutics

Bellerophon closes $7m round

January 28, 2019 By Sarah Faulkner

Bellerophon Therapeutics

Bellerophon Therapeutics (NSDQ:BLPH) last week closed an underwritten public offering of 10,000,000 shares of common stock at 70¢ apiece. The Warren, N.J.-based company also gave underwriters a 45-day option to buy up to an additional 1,500,000 shares of common stock at the same price. The gross proceeds of the offering were $7 million, Bellerophon reported. Earlier […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

Bellerophon prices $7m offering

January 24, 2019 By Sarah Faulkner

Bellerophon Therapeutics

Bellerophon Therapeutics (NSDQ:BLPH) said yesterday that it priced an underwritten public offering of 10,000,000 shares of its common stock at 70¢ apiece. The Warren, N.J.-based company also gave underwriters a 45-day option to buy an additional 1,500,000 shares of common stock at the same price. Bellerophon expects to reel in roughly $7 million in proceeds from […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

Bellerophon Therapeutics misses EPS estimates in Q4

March 16, 2018 By Sarah Faulkner

Bellerophon Therapeutics

Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed earnings expectations on Wall Street with its fourth-quarter and full-year results. The Warren, N.J.-based company posted a net loss of -$24.2 million, or -44¢ per share, for the 3 months ended Dec. 31. The company’s bottom-line losses grew -227% compared with the same period […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial

January 4, 2018 By Sarah Faulkner

Bellerophon Therapeutics

Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017

December 8, 2017 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, avitamedical, Bellerophon Therapeutics, biofilm, Biogen Idec, fractyllaboratories, novabay, Pediapharm, Tandem Diabetes Care

Bellerophon Therapeutics misses EPS estimates in Q3

November 8, 2017 By Sarah Faulkner

Bellerophon Therapeutics

Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed EPS expectations on Wall Street with its third quarter results. The Warren, N.J.-based company posted a net loss of -$7.6 million for the 3 months ended Sept. 30, for bottom-line loss of -81% compared with the same period last year. Adjusted to exclude 1-time […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

Bellerophon nabs $23m in private placement

September 27, 2017 By Sarah Faulkner

Bellerophon Therapeutics

Bellerophon Therapeutics (NSDQ:BLPH) said today that it inked a deal with new and existing investors to raise $23.4 million in a private placement of common stocks and warrants. The financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners, supported by existing investors like New Mountain Capital and Linde North America, the Warren, N.J.-based […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: Bellerophon Therapeutics

Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide

September 5, 2017 By Sarah Faulkner

Bellerophon Therapeutics

Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease. The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity. The data showed […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

Bellerophon shares fall despite Street-beating Q2 results

August 7, 2017 By Sarah Faulkner

Bellerophon Therapeutics

Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell today even though the company beat expectations on Wall Street with its second quarter results. The Warren, N.J.-based company posted a net loss of -$3.9 million with no sales for the 3 months ended June 30, for bottom-line growth of 23% compared with the same period last year. Adjusted to […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Vascular, Wall Street Beat Tagged With: Bellerophon Therapeutics

ATS Roundup: Emulate models viral infection in “asthma-on-a-chip”

May 24, 2017 By Sarah Faulkner

Emulate‘s small airway-lung chip could help researchers study viral-induced exacerbations of asthma, according to data presented this week at the American Thoracic Society’s annual meeting. The studies were conducted as part of the company’s partnership with (NYSE:MRK). The collaborative project was designed to enable development of new anti-inflammatory treatments for patients with asthma, according to Emulate. […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Emulate Inc, Merck, Mylan, pulmonx, Sunovion Pharmaceuticals, Theravance Biopharma

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS